NadirAlphaNA EN · DE · ES · FR · 中文 · PL

Abbott Laboratories Stock ABT

Abbott Laboratories · SEC filings · Reporting currency USD · Quarterly reporting · Figures as of Q3 2026 · updated 2026-10-27 · ISIN US0028241000 · WKN 850103

Abbott is a diversified global healthcare company operating across four main segments: Medical Devices, Diagnostics, Established Pharmaceuticals, and Nutrition. Abbott Laboratories stock (ABT): Quarterly and annual results since 2023 from Quarterly Report and SEC filings: revenue, earnings, balance sheet, cash flow and management guidance, every figure with its source. As of 10/2026, quarterly reporting. Stock analysis by NadirAlpha. Abbott Laboratories stock (ABT): listed on NYSE, index S&P 500, WKN 850103. NadirAlpha has evaluated 48 original documents, cross-checked every figure automatically and linked each to its source; sources as of 10/2026. Revenue Q3 2026: USD 13 billion (+14% year on year). Latest reading: Revenue accelerating, Guidance confirmed, Regulation.

Revenue accelerating Guidance confirmed strategy: Regulation

NadirAlpha editorial team · About us · Methodology

The new quarter, monitored by AI. · NadirAlpha follows every stock through its original filings: the latest figures against their history, guidance against actuals; neutral, continuously updated, every figure clickable with its source.
AI-generated report · not investment advice · figures extracted automatically; please verify against the linked original more
AI-generatedCreated with AI assistance from the company's linked original filings (transparency per Art. 50 EU AI Act). More about the tool: Claude Code.
Not investment adviceNeutral financial information, no recommendation, no investment research within the meaning of MiFID II.
Verify yourselfFigures are extracted automatically, errors are possible. Every figure is clickable with its source; the issuer's original documents are always authoritative.
EditorialThe texts (business model, current status, development and others) are written AI-editorially from the original reports alone, cross-checked automatically and backed with sources; the company's own account, no assessment of our own. Methodology
AI research · This page works as a source-backed data basis for further research with AI assistants such as Claude; every figure remains verifiable via the source links.

Abbott Laboratories Current Status

The current state of Abbott Laboratories at a glance, figures as of Q3 2026, with core figures and the key management statements from the latest filing. NadirAlpha methodology

Assessment by NadirAlpha, as of Q3 2026.

Abbott reported third-quarter 2026 revenue of 13,013 million, with reported sales growth of 14.5 percent and comparable sales growth of 7.0 percent 31. GAAP diluted EPS for the quarter was $0.53 and adjusted diluted EPS was $1.42 31. The quarter included FDA approvals for Libre Duo and the TactiFlex Duo Ablation Catheter, CE Mark approval for the Amulet 360 Left Atrial Appendage Occluder, and additional product launches across the portfolio 31. Abbott reaffirmed its full-year 2026 adjusted diluted EPS guidance range and projected full-year comparable sales growth of approximately 6.0 percent 31.
Management commentary on the 2026-Q3 results (8-K-EX99.1, 2026-10-21):

“Abbott delivered strong third-quarter results, reflecting balanced growth across our portfolio. With strong performance across multiple businesses and a robust pipeline of innovation, we are well-positioned to deliver sustainable growth in the years ahead.”

Robert B. Ford, Chairman and Chief Executive Officer 31
Revenue · 2026-Q313,013$ million+14.5 % vs. 2025-Q3
Net profit · 2026-Q3920$ million−44.0 % vs. 2025-Q3
EPS · 2026-Q30.53$−43.6 % vs. 2025-Q3
Revenue trend
Guidance
For FY2026, Abbott Laboratories guides EPS (non-GAAP) 5.5 to 5.55 $ (confirmed); Comparable sales growth ~6% (cut); Organic sales growth 6.5 to 7.5% (initiated). 31 For 2026-Q4, Abbott Laboratories guides EPS (non-GAAP) 1.62 to 1.67 $ (initiated). 31
Profitability
Abbott's third-quarter 2026 GAAP diluted EPS was $0.53, with adjusted diluted EPS at $1.42; the gap reflects items excluded from the adjusted measure 31. No operating income, net income, or free cash flow details for the third quarter of 2026 are available in the current inputs. The full-year 2026 adjusted EPS guidance range of $5.50 to $5.55 frames the expected earnings trajectory for the year 31.
Management view
Abbott reaffirmed its full-year 2026 adjusted diluted EPS guidance range of $5.50 to $5.55 and projected full-year comparable sales growth of approximately 6.0 percent 31. The board declared the 411th consecutive quarterly dividend of $0.63 per share; Abbott has increased its dividend payout for 54 consecutive years and is a member of the S&P 500 Dividend Aristocrats Index 31. Regulatory approvals and product launches completed this quarter span diabetes care, cardiovascular devices, cancer screening, and infant nutrition, reflecting continued portfolio expansion 31.
Risks (current)
Abbott is contesting three IRS Statutory Notices of Deficiency totaling $1.052 billion for tax years 2017 through 2020, with petitions filed in the U.S. Tax Court 20 30. Supply chain disruptions, patent infringement claims, potential loss of patent protection, and the costs and consequences of non-compliance with FDA and international regulatory requirements represent ongoing company-specific risks 26. Significant cybersecurity incidents and serious product safety concerns could result in business disruption, regulatory action, and material adverse effects on revenues and reputation 26.
New this reporting period
Abbott launched Libre Duo following FDA approval as the world's first dual glucose-ketone biowearable sensor for diabetes management, and received CE Mark approval for the Amulet 360 Left Atrial Appendage Occluder, a next-generation device for stroke risk reduction in atrial fibrillation patients 31. Similac 360 Total Care Made With Whole Milk launched as the first commercially sterile ready-to-feed liquid infant formula made with whole milk in the United States, and the TactiFlex Duo Ablation Catheter, Sensor Enabled, received FDA approval for atrial fibrillation treatment 31. SimpleScreen CRC, an FDA-approved blood-based colorectal cancer screening test for adults 45 and older, also launched this quarter, while the Exact Sciences acquisition completed March 23, 2026 continued to contribute to Diagnostics segment growth 31.

Abbott Laboratories Stock: Key Figures ($ million)

Revenue, margin, earnings and EPS of Abbott Laboratories per fiscal year, half-year and quarter in $ million, as of Q3 2026, as reported in the filing; restatements show the most recent filing version. NadirAlpha extracts all values automatically from the filings; errors are possible; please verify decision-relevant figures yourself by clicking through to the linked original. NadirAlpha methodology

All figures serve only to support your own investment decision and are not a recommendation; the company's original reports are authoritative.

Revenue ($ million) · annual basis, as reported
Net income ($ million) · annual basis, as reported
EPS ($) · annual basis, as reported
Operating cash flow ($ million) · annual basis, as reported
Revenue ($ million) · quarterly basis, as reported
Net income ($ million) · quarterly basis, as reported
EPS ($) · quarterly basis, as reported
Operating cash flow ($ million) · quarterly basis, as reported
Cash ($ million) · annual basis, as reported
Debt ($ million) · annual basis, as reported
Net Debt ($ million) · annual basis, as reported
Capex ($ million) · annual basis, as reported
FCF ($ million) · annual basis, as reported
D&A ($ million) · annual basis, as reported
Cash ($ million) · quarterly basis, as reported
Debt ($ million) · quarterly basis, as reported
Net Debt ($ million) · quarterly basis, as reported
Capex ($ million) · quarterly basis, as reported
FCF ($ million) · quarterly basis, as reported
D&A ($ million) · quarterly basis, as reported
Shown: the most recent fiscal years. Full history since FY2016 is on record.

Fiscal years

Amounts in $ million · EPS in $ per share · as reported
Abbott Laboratories stock: key figures on annual basis, FY2023 to FY2025, in $ million. Compiled by NadirAlpha from SEC filings.
PeriodRevenueOp. incomeNet incomeEPS ($)EPS adj. ($)OCFSource
FY202544,3288,0536,5243.725.15~9,56626
FY202441,9506,82513,4027.644.678,55818
FY202340,1096,4785,7233.264.44~7,26110

Quarters

Amounts in $ million · EPS in $ per share · as reported
Abbott Laboratories stock: key figures on quarterly basis, 2023-Q1 to 2026-Q3, in $ million. Compiled by NadirAlpha from SEC filings.
PeriodPublishedRevenueOp. incomeNet incomeEPS ($)EPS adj. ($)FCFCashNet DebtSource
2026-Q32026-10-2113,0131,3589200.531.42~–––131
2026-Q22026-07-1612,5931,6939280.531.31~–––129
2026-Q1*2026-04-1611,1641,3451,0770.611.15~9166,80327,24427
2025-Q4*2026-01-2211,4592,2511,7761.011.502,6268,5224,407125
2025-Q3*2025-10-1511,3692,0571,6440.941.30~2,2917,5115,43023
2025-Q2*2025-07-1711,1422,0521,7791.011.26~1,5456,9516,48621
2025-Q1*2025-04-1610,3581,6931,3250.761.09~9336,5326,71019
2024-Q4*2025-01-2210,9741,9119,2295.271.342,1487,6166,50917
2024-Q3*2024-10-1610,6351,8591,6460.941.21~2,1497,5587,42115
2024-Q2*2024-07-1810,3771,6691,3020.741.14~1,4276,9877,76713
2024-Q1*2024-04-179,9641,3861,2250.700.98~6276,2848,30211
2023-Q4*2024-01-2410,2411,7801,5940.911.19~2,2836,8967,7839
2023-Q3*2023-10-1810,1431,6471,4360.821.14~1,3176,7098,8197
2023-Q2*2023-07-209,9781,5421,3750.781.08~6967,8359,0115
2023-Q1*2023-04-199,7471,5091,3180.751.03~7639,1617,7393
* derived: values with formula provenance (hover); Q4 = FY − 9M · H2 = FY − H1 · EPS via implied shares · net debt = financial debt − cash · FCF = OCF − |capex|.
Columns not reported in this reporting cadence are hidden: Op. income (adj.), EBITDA (adj.) (not reported in any source for these periods).

Abbott Laboratories Balance Sheet & Cash Flow ($ million)

Balance sheet and cash flow of Abbott Laboratories up to Q3 2026 in $ million: net debt = financial debt minus cash, free cash flow = operating cash flow minus capex, every input sourced. NadirAlpha extracts all values automatically from the filings; errors are possible; please verify decision-relevant figures yourself by clicking through to the linked original. NadirAlpha methodology

Fiscal years

Amounts in $ million · as reported
Abbott Laboratories stock: balance sheet and cash flow on annual basis, FY2023 to FY2025, in $ million. Compiled by NadirAlpha from SEC filings.
PeriodPublishedCashDebtNet DebtD&AOCFCapexFCFSource
FY20252026-01-228,52212,9294,4073,1169,5662,1717,39525
FY20242025-01-227,61614,1256,5093,2188,5582,2076,35117
FY20232024-01-246,89614,6797,7833,2437,2612,2025,0599

Quarters

Amounts in $ million · as reported
Abbott Laboratories stock: balance sheet and cash flow on quarterly basis, 2023-Q1 to 2026-Q1, in $ million. Compiled by NadirAlpha from SEC filings.
PeriodPublishedCashDebtNet DebtD&AOCFCapexFCFSource
2026-Q12026-04-166,80334,04727,2448031,31539991627
2025-Q42026-01-228,52212,9294,4077923,3156892,626125
2025-Q32025-10-297,51112,9415,4307912,7874962,29124
2025-Q22025-07-176,95113,4376,4867772,0475021,54521
2025-Q12025-04-166,53213,2426,7107561,41748493319
2024-Q42025-02-217,61614,1256,5098072,8687202,14818
2024-Q32024-10-167,55814,9797,4218012,7055562,14915
2024-Q22024-07-186,98714,7547,7678051,9605331,42713
2024-Q12024-05-026,28414,5868,3028051,02539862712
2023-Q42024-01-246,89614,6797,7838133,0387552,2839
2023-Q32023-10-186,70915,5288,8198241,8775601,3177
2023-Q22023-07-207,83516,8469,0118001,2035076965
2023-Q12023-04-199,16116,9007,7398061,1433807633
Debt = long-term + current · Net debt = debt − cash · FCF = OCF − capex.

Abbott Laboratories Guidance Tracking (latest per metric/period · 16/26)

All forecasts (guidance) of the Abbott Laboratories management and their later outcome: per metric and period the most recent statement applies, the status is checked against the reported actuals. NadirAlpha methodology

Actuals: EPS in $ per share · ratios in %

Direction: confirmedcutinitiatedraised Verdict: beatin linemisspending

Abbott Laboratories: guidance and actuals per metric and period, 26 entries. Compiled by NadirAlpha from SEC filings.
For periodGuided onMetricGuidedActualVerdictDirectionSource
FY20262026-10-21EPS (non-GAAP)5.5–5.55–31
FY20262026-10-21Comparable sales growth~6%–31
FY20262026-01-22Organic sales growth6.5–7.5%–25
2026-Q42026-10-21EPS (non-GAAP)1.62–1.67–31
2026-Q32026-07-16EPS (non-GAAP)1.38–1.46––29
2026-Q22026-04-16EPS (non-GAAP)1.25–1.31––27
2026-Q12026-01-22EPS (non-GAAP)1.12–1.18––25
FY20252025-10-15EPS (non-GAAP)5.12–5.18––23
FY20252025-10-15Organic sales growth-19–8%––23
FY20252025-07-17Operating margin~23.5%18.221
FY20252025-07-17Organic sales growth, excluding COVID-19 testing-related sales7.5–8%––21
FY20252025-07-17Organic sales growth, including COVID-19 testing-related sales6–7%––21
FY20252025-01-22Organic growth7.5–8.5%––17
2025-Q32025-07-17EPS (non-GAAP)1.28–1.32––21
2025-Q22025-04-16EPS (non-GAAP)1.23–1.27––19
2025-Q12025-01-22EPS (non-GAAP)1.05–1.09––17
FY20242024-10-16EPS (GAAP)3.34–3.47.6415
FY20242024-10-16EPS (non-GAAP)4.64–4.74.6715
FY20242024-10-16Organic sales growth (excluding COVID-19 testing-related sales)9.5–10%––15
2024-Q42024-10-16EPS (GAAP)0.96–1.025.2715
2024-Q42024-10-16EPS (non-GAAP)1.31–1.371.3415
2024-Q22024-04-17EPS (GAAP)0.69–0.730.7411
2024-Q22024-04-17EPS (non-GAAP)1.08–1.12––11
FY20232023-10-18EPS (GAAP)3.14–3.183.267
FY20232023-10-18EPS (non-GAAP)4.42–4.46––7
FY20232023-07-20COVID-19 testing-related sales~1,300––5

Abbott Laboratories Stock: Price & Chart

Interactive price chart of Abbott Laboratories stock (TradingView) and the trend of key figures from the core tables; the chart loads only after a click and then connects to TradingView. NadirAlpha methodology

Daily candles with news and earnings markers. Loads only on click.

Advertisement · affiliate links; we may earn a commissionAffiliate partnerships help us keep these reports free and regularly updated.

Abbott Laboratories Event Timeline

This timeline collects the material events of Abbott Laboratories from the original reports: guidance changes, revenue and margin signals, strategy shifts, product and M&A announcements, grouped by quarter. NadirAlpha methodology

Overview: one dot per event · click jumps to the period
earningsrevenuemarginguidancestrategy2023-Q12023-Q32024-Q12024-Q3FY20242025-Q22025-Q42026-Q12026-Q3
2026 · 8 events

Revenue accelerating 2026-10-21
Third-quarter comparable sales growth 7.0 percent; reported sales growth 14.5 percent 31
Guidance confirmed 2026-10-21
Full-year 2026 adjusted diluted EPS guidance reaffirmed at $5.50 to $5.55, with comparable sales growth of approximately 6.0 percent 31
Regulation 2026-10-21
FDA approval for Libre Duo, the world's first dual glucose-ketone biowearable sensor for diabetes management 31

“Our second-quarter results reflect the momentum we are building. We expect this momentum to continue and drive accelerating sales and earnings growth in the second half of the year.”

Robert B. Ford, Chairman and Chief Executive Officer 29

“Abbott stands by its products and the information it provided about them, and it is seeking review of the ruling from the Supreme Court of Missouri.”

Revenue accelerating 2026-07-16
Second-quarter comparable sales growth 4.8 percent; reported sales growth 13.0 percent 29
Guidance raised 2026-07-16
Full-year 2026 adjusted diluted EPS guidance raised to $5.45 to $5.60 from previous range of $5.38 to $5.58 29
Regulation 2026-07-16
CE Mark secured for Libre Duo, the world's first dual glucose-ketone biowearable sensor 29

“Our first-quarter results were aligned with our expectations to start the year. The acquisition of Exact Sciences adds another high-growth business to the Abbott portfolio, further strengthening our confidence in delivering accelerating growth as we move through the year.”

Robert B. Ford, chairman and chief executive officer 27
Margin compressing 2026-04-29
Gross profit margin 52.4% vs 52.8% in prior year, reflecting higher costs and unfavorable foreign exchange 28
Acquisition 2026-04-29
Exact Sciences acquisition completed March 23, 2026 for approximately $20.6 billion, funded primarily through $20.0 billion long-term debt issuance, adding Cologuard, Oncotype DX, and Cancerguard to the portfolio 28
2025 · 14 events

Net income halved 2026-02-20
Net income more than halved YoY (13,402.0 to USD 6,524.0 million, -51%). 26

“In 2025, we expanded margins and achieved double-digit earnings per share growth, our new product pipeline was highly productive, and we took important strategic steps to shape the company for the future. We're well positioned for accelerating growth in 2026.”

Robert B. Ford, Chairman and Chief Executive Officer 25
Revenue accelerating ◦ 2026-01-22
Medical Devices segment achieved 10.4 percent organic growth in Q4 2025 with strong performance across Electrophysiology, Heart Failure, Diabetes Care, and Rhythm Management 25
Acquisition 2026-01-22
Announced agreement to acquire Exact Sciences to enter the cancer diagnostics market; enterprise value approximately $23 billion, transaction expected to close in Q2 2026 25
Regulation 2026-01-22
FDA approved Volt PFA System, bringing Abbott's first pulsed field ablation offering to the United States 25
Net income halved 2026-01-22
Net income more than halved YoY (9,229.0 to USD 1,776.0 million, -81%). 125

“Our third-quarter results demonstrate our ability to deliver consistent, high-quality performance. Our differentiated product pipeline continues to power our performance and positions Abbott to deliver durable long-term value to our shareholders.”

Robert B. Ford, Chairman and Chief Executive Officer 23
Revenue accelerating ◦ 2025-10-15
Reported sales growth of 6.9 percent; organic sales growth of 5.5 percent, or 7.5 percent excluding COVID-19 testing-related sales 23
Margin expanding 2025-10-15
Adjusted operating margin of 23.0 percent reflecting a 40 basis point increase 23
Regulation 2025-10-15
Regulatory approval received in Japan for TriClip, minimally invasive treatment for tricuspid regurgitation 23

“Halfway through the year, we delivered high single-digit organic sales growth, double-digit EPS growth, significantly expanded our margin profiles, and continued to advance key programs through our new product pipeline. We see this momentum carrying into 2026.”

Robert B. Ford, Chairman and Chief Executive Officer 21
Regulation 2025-07-30
U.S. District Court granted summary judgment in favor of Abbott in first bellwether preterm infant formula case 22
Revenue accelerating ◦ 2025-07-17
Organic sales growth of 6.9 percent, or 7.5 percent excluding COVID-19 testing sales 21
Regulation 2025-07-17
FDA approved Tendyne transcatheter mitral valve replacement system, described as first-of-its-kind device for mitral valve disease 21

“Once again, Abbott's diversified business model delivered top-tier sales and EPS growth. It is this diversification and execution that allows Abbott to navigate through periods of uncertainty and continually deliver sustainable growth.”

Robert B. Ford, chairman and chief executive officer 19
Revenue accelerating ◦ 2025-04-16
Organic sales growth of 6.9 percent, or 8.3 percent excluding COVID-19 testing sales; Medical Devices segment grew 12.6 percent excluding foreign exchange 19
Margin expanding 2025-04-16
Adjusted operating margin of 21.0 percent reflecting a 130 basis point increase 19
Regulation 2025-04-16
CE Mark obtained for Volt Pulse Field Ablation System to treat atrial fibrillation 19
2024 · 14 events

“Abbott stands by its products and the information it provided about them”

Net income doubled 2025-02-21
Net income more than doubled YoY (5,723.0 to USD 13,402.0 million, +134%). 18

“We finished the year with very strong momentum. Sales growth and earnings per share growth in the fourth quarter were the highest of the year. We continued our track record for delivering on our commitments by achieving the upper end of our initial guidance ranges for 2024 and are well-positioned to deliver another year of strong growth in 2025.”

Robert B. Ford, Chairman and Chief Executive Officer 17
Net income doubled 2025-02-21
Net income more than doubled YoY (1,594.0 to USD 9,229.0 million, +479%). 125
Revenue accelerating ◦ 2025-01-22
Q4 sales of USD 10,974 million, reported growth of 7.2%; full-year underlying base business organic growth of 9.6% excluding COVID-19 testing sales 17
Margin expanding 2025-01-22
Full-year 2024 gross margin improved 60 basis points on a GAAP basis compared to 2023 17
Guidance initiated 2025-01-22
Full-year 2025 adjusted diluted EPS projected at $5.05-$5.25, reflecting double-digit growth at the midpoint 17

“Our results this quarter demonstrate the strength of our diversified business model. We're well-positioned to achieve the upper end of our initial guidance ranges for the year and have great momentum heading into next year.”

Robert B. Ford, Chairman and Chief Executive Officer 15
Revenue accelerating ◦ 2024-10-16
Q3 sales of USD 10,635 million, organic growth of 8.2% excluding COVID-19 impact; Medical Devices led with 13.3% organic growth 15
Guidance raised 2024-10-16
Raised midpoint of full-year 2024 adjusted diluted EPS guidance range to $4.64-$4.70 15
Partnership 2024-10-16
Partnership announced with Medtronic to connect Abbott's CGM system with Medtronic's insulin delivery devices 15

“We achieved another quarter of strong growth in our underlying base business. We have a lot of positive momentum heading into the second half of the year and are raising our full-year guidance.”

Robert B. Ford, Chairman and Chief Executive Officer 13
Margin expanding 2024-07-31
Gross profit margin improved to 51.1% in Q2 2024 from 50.1% in Q2 2023, driven by favorable pricing and margin improvement initiatives 14
Revenue accelerating ◦ 2024-07-18
Q2 sales of USD 10,377 million with organic growth of 9.3% excluding COVID-19 tests; Medical Devices organic growth of 12.1% 13
New market 2024-07-18
FDA cleared Lingo and Libre Rio over-the-counter CGM systems in June 2024, entering the consumer glucose monitoring market without prescription requirement 13

“Our first-quarter results reflect a strong start to the year, and we are raising our full-year sales and EPS guidance. This was the fifth consecutive quarter that we delivered double-digit organic sales growth in our underlying base business, which included particularly strong results in Medical Devices and Established Pharmaceuticals.”

Robert B. Ford, Chairman and Chief Executive Officer 11
Revenue accelerating ◦ 2024-04-17
Q1 sales of USD 9,964 million, with organic base business growth of 10.8%, the fifth consecutive quarter of double-digit growth 11
Guidance raised 2024-04-17
Full-year 2024 adjusted diluted EPS guidance raised to $4.55-$4.70 following Q1 results 11
Regulation 2024-04-17
FDA approved TriClip, first minimally invasive treatment for tricuspid regurgitation 11
2023 · 12 events

“The strength and diversity of the Abbott portfolio drove our success in 2023. We're entering 2024 with a lot of positive momentum, and with our highly productive pipeline, we're well-positioned for growth in 2024 and beyond.”

Robert B. Ford, Chairman and Chief Executive Officer 9
Revenue accelerating ◦ 2024-01-24
Q4 reported sales of USD 10,241 million increased 1.5 percent; organic base business growth was 11.0 percent excluding COVID-19 testing sales 9
Guidance initiated 2024-01-24
Abbott issued 2024 financial guidance for GAAP diluted EPS of $3.20 to $3.40 and adjusted diluted EPS of $4.50 to $4.70, with projected organic sales growth excluding COVID-19 testing of 8.0 to 10.0 percent 9
New market 2024-01-24
First-in-human procedures conducted using the new Volt Pulsed Field Ablation System for heart rhythm disorder treatment; U.S. clinical trial approval anticipated in the first half of 2024 9

“The investments we made during the pandemic continue to drive broad-based growth across our underlying base business. We're on track to deliver on the financial commitments we set at the beginning of the year, and the momentum we're building across the portfolio positions us well as we head into 2024.”

Robert B. Ford, Chairman and Chief Executive Officer 7
Acquisition 2023-11-01
Abbott acquired Bigfoot Biomedical on September 22, 2023 to develop connected solutions for diabetes management 8
Revenue accelerating ◦ 2023-10-18
Q3 organic base business growth of 13.8 percent excluding COVID-19 testing impact, with reported sales of USD 10,143 million 7
Guidance raised 2023-10-18
Abbott narrowed the full-year 2023 EPS guidance range and raised the midpoint of adjusted diluted EPS guidance to $4.42 to $4.46 7

“We're achieving strong growth in our underlying base business. We expect our highly productive pipeline to sustain the momentum we're building this year and position us well for growth in the future.”

Robert B. Ford, Chairman and Chief Executive Officer 5
Margin compressing 2023-08-03
Gross profit margin decreased from 52.8 percent in the first half of 2022 to 50.3 percent in the first half of 2023, reflecting lower COVID-19 test sales, foreign exchange impact, and higher manufacturing input costs 6
Acquisition 2023-08-03
Abbott completed the acquisition of Cardiovascular Systems Inc. for $851 million, adding atherectomy technology to the vascular device portfolio 6
Regulation 2023-07-20
FDA approved the AVEIR dual-chamber leadless pacemaker system in June 2023 5

“Our first-quarter results reflect a very strong start to the year. Growth in our underlying base businesses accelerated, including particularly strong results in Medical Devices, Established Pharmaceuticals and Nutrition.”

Robert B. Ford, Chairman and Chief Executive Officer 3
Revenue decelerating 2023-04-19
Q1 reported sales of USD 9,747 million declined 18.1 percent as COVID-19 testing sales normalized from $3.3 billion in Q1 2022 to $730 million; excluding COVID-19 testing, base business sales grew 4.9 percent 3
Guidance confirmed 2023-04-19
Full-year 2023 guidance confirmed at GAAP diluted EPS $3.05 to $3.25 and adjusted diluted EPS $4.30 to $4.50 3
Regulation 2023-04-19
FDA approved the Navitor second-generation transcatheter aortic valve implantation system for severe aortic stenosis patients and cleared FreeStyle Libre for integration with automated insulin delivery systems 3

Abbott Laboratories Business Model

What Abbott Laboratories does and how the company earns its money, written AI-editorially from the original reports alone, without any assessment of our own. NadirAlpha methodology

Abbott is a diversified global healthcare company operating across four main segments: Medical Devices, Diagnostics, Established Pharmaceuticals, and Nutrition. The Medical Devices segment includes cardiovascular, neuromodulation, and diabetes care products, with the FreeStyle Libre continuous glucose monitoring system representing a significant ongoing revenue contributor. The Diagnostics segment provides laboratory-based and rapid diagnostic testing products and services, a business expanded through the Exact Sciences acquisition in early 2026. Abbott's Established Pharmaceuticals segment sells branded generic medicines primarily in emerging markets, while the Nutrition segment markets infant, toddler, and adult nutritional products under brands including Similac and Ensure.

Abbott Laboratories Stock: Share-Price Drivers

The drivers of Abbott Laboratories stock from the company's perspective: demand, prices, costs and capacity as the investor relations reports describe them. NadirAlpha methodology

Medical Devices growth led by Diabetes Care (FreeStyle Libre) and Electrophysiology
Abbott's Medical Devices segment is the largest revenue contributor at 5,539 million in the first quarter of 2026 (28), and within it Diabetes Care revenue reached 4,268 million over the first six months of 2026, up 12.1 percent, while Electrophysiology rose 15.3 percent (30); group revenue reached USD 13,013 million in the third quarter of 2026 (131)
Diabetes Care / FreeStyle Libre continuous glucose monitoring
Abbott's Diabetes Care revenue was 4,268 million over the first six months of 2026, up 12.1 percent (30); the company extended the franchise with the Libre Duo launch (31) and FreeStyle Libre integration with automated insulin delivery systems (10)
Electrophysiology and pulsed field ablation
Abbott's Electrophysiology revenue was 1,649 million over the first six months of 2026, up 15.3 percent (30); the company launched the Volt Pulsed Field Ablation System (26) and received CE Mark for the Volt PFA System (25)
Structural Heart devices
Abbott's Structural Heart revenue was 1,175 million over the first six months of 2026, up 5.7 percent (30), supported by TriClip regulatory approval in Japan (26), the Tendyne transcatheter mitral valve replacement system (26) and Navitor (26)
Rhythm Management and leadless pacing
Abbott's Rhythm Management revenue was 1,427 million over the first six months of 2026, up 13.4 percent (30), with the AVEIR dual chamber leadless pacemaker system (14) and ASSERT-IQ implantable cardiac monitor (18)
Established Pharmaceuticals in emerging markets
Abbott's Established Pharmaceutical Products Key Emerging Markets revenue was 2,253 million over the first six months of 2026, up 11.3 percent (30)
Diagnostics rapid and molecular testing
Abbott's Diagnostic Products Rapid and Molecular revenue was 1,567 million over the first six months of 2026, down 7.4 percent (30), reflecting the roll-off of COVID-19 related testing; Core Laboratory rose 6.1 percent (30)
Nutrition, U.S. demand
Abbott's U.S. Pediatric Nutritionals revenue was 1,036 million over the first six months of 2026, down 11.9 percent, and U.S. Adult Nutritionals was 679 million, down 7.8 percent (30), while International Pediatric rose 2.4 percent (30)
Exact Sciences acquisition
Abbott announced the planned Exact Sciences acquisition in November 2025 (31), which has not yet closed

Sector trend: Across Abbott's med-tech and diagnostics markets, demand for diabetes care, electrophysiology and structural heart devices is heading higher, while COVID-era rapid and molecular diagnostics continue to decline and U.S. nutrition demand is softer (30). Profitability is improving and full-year guidance was confirmed, even as reported revenue growth is decelerating (131).

Abbott Laboratories Revenue by Type (as of 2026-Q3 · USD million · 34/57)

The segments of Abbott Laboratories in the company's own definition, each row with its basis (3, 6 or 12 months), rows in grey are no longer reported separately. NadirAlpha methodology

Abbott Laboratories: revenue by segment, as of 2026-Q3, in USD million. Compiled by NadirAlpha from SEC filings.
SegmentSinceRevenueGrowthSource
Period 2026-Q2 (6M)
Diagnostic Products – Rapid and Molecular2026-Q21,567-7.4%30
Diagnostic Products – Cancer Diagnostics2026-Q21,015–30
Established Pharmaceutical Products – Other Emerging Markets2026-Q26728.6%30
Diagnostic Products – Core LaboratoryFY20242,6906.1%30
Nutritional Products – International Adult NutritionalsFY20241,504-1.5%30
Nutritional Products – U.S. Pediatric NutritionalsFY20241,036-11.9%30
Nutritional Products – International Pediatric NutritionalsFY20249422.4%30
Nutritional Products – U.S. Adult NutritionalsFY2024679-7.8%30
Medical Devices – Diabetes CareFY20234,26812.1%30
Established Pharmaceutical Products - Key Emerging MarketsFY20232,25311.3%30
Medical Devices - ElectrophysiologyFY20231,64915.3%30
Medical Devices - VascularFY20231,5807.7%30
Medical Devices - Rhythm ManagementFY20231,42713.4%30
Medical Devices - Structural HeartFY20231,1755.7%30
Medical Devices - Heart FailureFY202379011.7%30
Medical Devices - NeuromodulationFY20235034.3%30
Period 2026-Q1 (3M)
Medical Devices2023-Q15,539–28
Diagnostics2023-Q12,1806.1%27
Diagnostic Products2023-Q12,180–28
Nutrition2023-Q12,0176%27
Nutritional Products2023-Q12,017–28
Established Pharmaceuticals2023-Q11,42613.2%27
Established Pharmaceutical Products2023-Q11,426–28
Period 2025-Q1 (3M)
Total2025-Q110,358–20
Medical Devices Total2025-Q14,895–20
Nutritional Products Total2025-Q12,146–20
Diagnostic Products Total2025-Q12,054–20
Established Pharmaceutical Products Total2025-Q11,260–20
Nutritional Products - Adult Nutritionals2025-Q11,105–20
Nutritional Products - Pediatric Nutritionals2025-Q11,041–20
Diagnostic Products - Rapid DiagnosticsFY2024613–20
Diagnostic Products - Point of CareFY2024142–20
Diagnostic Products - MolecularFY2024122–20
Established Pharmaceutical Products - OtherFY2023295–20
Period 2024-Q2 (6M)
Diabetes Care2023-Q11,64815.8%13
Period 2024-Q1 (3M)
Adult Nutrition2023-Q11,0591.5%11
Pediatric Nutrition2023-Q11,0099.2%11
Period FY2023 (12M)
Diagnostics - Core LaboratoryFY20235,1595.5%10
Diagnostics - Rapid DiagnosticsFY20233,690-63.3%10
Nutritional Products - International AdultFY20232,7846.2%10
Nutritional Products - U.S. PediatricFY20231,97726.6%10
Nutritional Products - International PediatricFY20231,9572%10
Nutritional Products - U.S. AdultFY20231,4365.8%10
Diagnostics - MolecularFY2023574-42.3%10
Diagnostics - Point of CareFY20235657.5%10
Period 2023-Q2 (3M)
Core Laboratory2023-Q11,2935.9%5
Rapid Diagnostics2023-Q1741-72.8%5
Vascular2023-Q17159.3%5
Rhythm Management2023-Q15836.3%5
Electrophysiology2023-Q155314.1%5
Structural Heart2023-Q149813.3%5
Heart Failure2023-Q12959.6%5
Neuromodulation2023-Q122715.1%5
Point of Care2023-Q11421.9%5
Molecular2023-Q1141-33.3%5
Period 2023-Q1 (3M)
Key Emerging Markets2023-Q19120.7%3
Established Pharmaceuticals Other2023-Q127715%3

Abbott Laboratories Products & announcements (19/60 active+recent)

60 product announcements of Abbott Laboratories since 2023, grouped by year; active means still mentioned in the most recent reports, nothing is deleted. NadirAlpha methodology

Status: PlannedLaunched

Abbott Laboratories: product announcements from the filings, 60 entries. Compiled by NadirAlpha from SEC filings.
Product/LineSinceStatusSource
2028
Cardiovascular device manufacturing facility in Georgia202821
2026
SimpleScreen CRC2026-0931
Similac 360 Total Care Made With Whole Milk2026-0831
Libre Duo2026-0831
Libre Duo dual glucose-ketone biowearable sensor2026-0530
Amulet 360 FDA submission2026-0529
TECTONIC U.S. pivotal trial (2x)2026-0419
Heart Rhythm Society presentation of pulsed field ablation and conduction system pacing data2026-0429
Amulet 360 Left Atrial Appendage Occluder (2x)2026-0231
Collaboration with AtaCor Medical for EV-ICD system development2026-0127
2025
Volt PFA System CE Mark2025-1225
FlexPulse U.S. IDE trial enrollment2025-0421
AVEIR Conduction System Pacing clinical feasibility study data2025-0421
Volt Pulse Field Ablation System CE Mark2025-0320
Volt Pulsed Field Ablation System (2x)202526
TriClip regulatory approval in Japan202526
Tendyne transcatheter mitral valve replacement system202526
Navitor expanded indication CE Mark202526
2024
FreeStyle Libre continuous glucose monitor (2x)2024-1227
Navitor2024-1217
AVEIR2024-1217
VOLT-AF IDE trial enrollment completion2024-0915
U.S. launch of Lingo2024-0916
Lingo continuous glucose monitoring system (2x)2024-0615
i-STAT TBI test FDA approval2024-0411
Volt-AF IDE clinical study initiated2024-0411
TriClip FDA approval for tricuspid regurgitation treatment2024-0416
Esprit below-the-knee system FDA approval for peripheral artery disease2024-0416
Esprit below-the-knee (BTK) system2024-0413
i-STAT TBI cartridge for traumatic brain injury2024-0318
Volt CE Mark clinical study enrollment completed2024-0311
Insulet Omnipod 5 with FreeStyle Libre 2 Plus CE Mark approval (3x)2024-0211
Tandem t:slim X2 insulin pump integration with FreeStyle Libre 2 Plus (3x)2024-0116
Protality brand launch2024-0111
Five Year Revolving Credit Agreement2024-0112
ZonePerfect product line discontinuation202426
TriClip tricuspid valve repair device202418
Navitor and TriClip products in Structural Heart202418
Lingo and Libre Rio over-the-counter CGM systems (2x)202414
Esprit BTK peripheral artery disease system202418
Alinity testing platform continued deployment202418
Advisor HD Grid X Mapping Catheter, Sensor Enabled202418
ASSERT-IQ implantable cardiac monitor202418
2023
GLP systems Track laboratory automation system2023-1218
Alinity h-series hematology system2023-098
FreeStyle Libre 2 system expanded reimbursement in France2023-065
TriClip202317
TactiFlex Duo Ablation Catheter CE Mark (3x)202310
Navitor transcatheter aortic valve (3x)202310
MitraClip product20234
FreeStyle Libre integration with automated insulin delivery systems (2x)202310
Eterna rechargeable spinal cord stimulation system202310
Epic Max stented tissue valve202310
Amulet (2x)202317
2022
Sturgis facility partial production restart2022-0710
Sturgis facility FDA consent decree2022-0510
Voluntary infant formula product recall2022-0310
Sturgis facility infant formula recall2022-0210
EnSite X EP System with EnSite Omnipolar Technology202210
Aveir leadless pacemaker (5x)202214

Abbott Laboratories Transactions & Events (10)

Transactions of Abbott Laboratories since 2023: acquisitions, disposals, agreements and regulation, deliberately including smaller items; purchase prices only when the company names them. NadirAlpha methodology

Acquisitions · 5Partnerships/contracts · 3Divestitures/exits · 1older: 1 (in the table)
202320242025

Acquisitions by Abbott Laboratories

Abbott Laboratories: Acquisitions, 6 entries. Compiled by NadirAlpha from SEC filings.
Transaction / stakeDateTypeSource
2025
Exact Sciences2025-11Completed31
2023
Bigfoot acquisition (3x)2023-09Completed26
Bigfoot Biomedical2023-09Completed18
Cardiovascular Systems, Inc. (2x)2023-04Completed26
CSI acquisition (2x)2023-04Completed18
2021
Walk Vascular acquisition for thrombectomy system2021-09Completed10

Divestitures and exits by Abbott Laboratories

Abbott Laboratories: Divestitures / exits, 1 entries. Compiled by NadirAlpha from SEC filings.
Transaction / stakeDateTypeSource
2022
Pediatric nutrition business exit in China2022-12Divested9

Partnerships and contracts of Abbott Laboratories

Abbott Laboratories: Partnerships & contracts, 3 entries. Compiled by NadirAlpha from SEC filings.
Transaction / stakeDateTypeSource
2024
Medtronic partnership for CGM-insulin pump integration2024-08Agreement15
Global partnership with Medtronic to connect Abbott CGM system with Medtronic insulin delivery devices2024-08Agreement16
2023
mAbxience biosimilar collaboration expansion2023-09Agreement7

Abbott Laboratories Risks (45 since the annual report of 2026-02-20, 119 tracked in total)

NadirAlpha lists 45 active risks of Abbott Laboratories from the filings, the category as a coloured dot with legend, the wording as a short summary of the filing with no assessment of our own. NadirAlpha methodology

Category: FinancialLegalRegulatoryMacroTechnologyESGCompetitionCustomersSupply chainGeopolitics

Abbott Laboratories: risk factors as reported, 45 since the last annual report, 119 tracked. Compiled by NadirAlpha from SEC filings.
RiskCategoryLast reported
Abbott Laboratories: first mention in 10-Q quarterly report of 2026-07-28 (2026-Q2), source 30
IRS proposed income reallocation adjustments between Abbott U.S. entities and foreign affiliates across multiple tax years; Abbott believes adjustments lack merit.=
2020 IRS SNOD contests deduction with estimated $440 million cash tax benefit in different taxable year under applicable U.S. tax law.=
Missouri Court of Appeals affirmed $495 million Gill verdict in May 2026; Abbott seeking review from Missouri Supreme Court.=
Six shareholder derivative lawsuits consolidated regarding infant formula manufacturing settled with final court approval in June 2026.=
Abbott expects continued debate over availability, method of delivery, and payment for healthcare products and services in primary markets.=
OECD Pillar 2 proposes 15 percent minimum tax on in-scope multinational corporations on country-by-country basis; OECD released January 2026 guidance exempting U.S.-parented groups.=
Abbott Laboratories: first mention in 10-Q quarterly report of 2026-04-29 (2026-Q1), source 28
Abbott contesting IRS Statutory Notices of Deficiency totaling $1.052 billion for 2019, 2017-2018, and 2020 tax years on income reallocation.=
OECD Pillar 2 minimum tax of 15 percent on multinational corporations; January 2026 guidance exempts U.S.-parented groups; Abbott monitoring impact.=
Abbott's primary markets subject to substantial government regulations; debate over healthcare product availability, delivery, and payment expected to continue.=
Abbott Laboratories: first mention in 10-K annual report of 2026-02-20 (FY2025), source 26
Malaysian tax authority assessed $413 million property capital gains tax; Penang High Court upheld assessment in October 2025; Abbott filed appeal.2026-Q2
2026-07-28 30
Abbott may fail to complete acquisitions in timely or cost-effective manner and may not realize expected benefits.=
Exact Sciences acquisition will add approximately $20 billion of debt, reducing financial flexibility.=
Multiple unresolved tax matters across numerous jurisdictions; Abbott reserves for uncertain tax positions=
Government cost containment efforts and reimbursement changes could reduce prices and usage of Abbott's products.=
Manufacturing problems could lead to product recalls, liability costs, and material adverse effects on revenues.=
Abbott's R&D efforts may not produce commercially successful products or may be rendered obsolete by competitors.=
Labor disputes, strikes, or union activity could adversely affect operations and profitability.=
TCJA transition tax obligation of $205 million remaining, payable in 2026=
Climate change, extreme weather, natural disasters, and public health crises could disrupt operations.=
Deterioration in economic conditions could increase collection risk and reduce profitability.=
Trade tariffs, geopolitical tensions, and currency volatility could disrupt supply chain and operations.=
Cost containment efforts by governments and private organizations could reduce product pricing and revenues.=
EU IVDR transition compliance extended to December 2029 with additional premarket and post-market requirements=
EU MDR transition extended to December 31, 2028 with additional regulatory requirements on manufacturers=
OECD Pillar 2 minimum tax proposal at 15 percent; US-parented groups exempted as of January 5, 2026=
Changes in tax laws and OECD proposals could materially affect effective tax rate and financial condition.=
Competitors' products and technological advances may reduce demand for Abbott's products.=
Abbott Laboratories: first mention in 10-Q quarterly report of 2025-10-29 (2025-Q3), source 24
Defendant in numerous lawsuits alleging preterm infants developed necrotizing enterocolitis from Abbott preterm infant formula products; Missouri jury awarded $495 million in July 2024.2026-Q2
2026-07-28 30
Abbott disputed IRS assessments of $417M (2019), $192M (2017-2018), and $443M (2020) and filed petitions in Tax Court=
Challenging market conditions in China impacting Diagnostics sales; volume-based procurement programs limit growthFY2025
2026-02-20 26
Abbott Laboratories: first mention in 10-Q quarterly report of 2025-07-30 (2025-Q2), source 22
SEC investigation into infant formula business and public disclosures concluded without enforcement action.=
Abbott Laboratories: first mention in 10-Q quarterly report of 2025-04-30 (2025-Q1), source 20
Abbott faces NEC lawsuits from preterm formula; one jury verdict $495 million=
Abbott Laboratories: first mention in 10-K annual report of 2025-02-21 (FY2024), source 18
Abbott faces product liability claims alleging injuries from preterm infant formula; 1,760 lawsuits pending as of January 31, 2026.FY2025
2026-02-20 26
Abbott Laboratories: first mention in 10-Q quarterly report of 2024-10-31 (2024-Q3), source 16
Numerous lawsuits alleging preterm infants developed necrotizing enterocolitis from Abbott formula products.2025-Q2
2025-07-30 22
Abbott Laboratories: first mention in 10-Q quarterly report of 2024-07-31 (2024-Q2), source 14
IRS issued Statutory Notices of Deficiency for 2019, 2017/2018, and 2020 tax years totaling $1.052 billion; Abbott contests all through U.S. Tax Court petitions.2026-Q2
2026-07-28 30
Abbott Laboratories: first mention in 10-K annual report of 2024-02-16 (FY2023), source 10
Serious safety concerns could result in product discontinuation and material adverse effects on revenues and reputation.FY2025
2026-02-20 26
Disruptions to Abbott's global supply chain could negatively affect results of operations.FY2025
2026-02-20 26
Expiration or loss of patent protection could reduce future revenues and operating earnings.FY2025
2026-02-20 26
Abbott faces patent infringement claims from competitors which could result in significant damages or injunctions.FY2025
2026-02-20 26
Compliance with FDA and international regulations is costly and non-compliance can result in product recalls and sanctions.FY2025
2026-02-20 26
Significant cybersecurity incident could result in business disruption, regulatory action, and material adverse effects.FY2025
2026-02-20 26
Russia and Ukraine operations represent 2 percent of revenues; no material impact to date anticipatedFY2025
2026-02-20 26
Abbott Laboratories: first mention in 10-Q quarterly report of 2023-11-01 (2023-Q3), source 8
IRS issued three SNODs totaling $1.052 billion for tax years 2017-2020 regarding income reallocation; Abbott contesting via Tax Court petitions.2025-Q1
2025-04-30 20
Abbott Laboratories: first mention in 8-K-EX99.1 earnings release of 2023-10-18 (2023-Q3), source 7
Continued decline in COVID-19 testing-related sales affecting Diagnostics and Rapid Diagnostics segmentsFY2025
2026-02-20 26
Abbott Laboratories: first mention in 10-Q quarterly report of 2023-05-04 (2023-Q1), source 4
Fluctuation in foreign currency exchange rates adversely affects financial statements and projected earnings.FY2025
2026-02-20 26
= last mention identical with the first mention (same source)

Abbott Laboratories Reported KPIs (as disclosed) (612)

The story KPIs of Abbott Laboratories that standard databases usually miss, grouped by publication, most recent first, with source number. NadirAlpha methodology

Company-specific KPIs verbatim from the filings (English, as disclosed; not normalised). Balance-sheet and boilerplate items filtered.
Abbott Laboratories: reported KPIs as disclosed, 612 entries. Compiled by NadirAlpha from SEC filings.
KPIValue / changeSource
Abbott Laboratories, published 2026-07-28, period 2026-Q2
Working capital at June 306.7 billion30
Working capital at December 319.5 billion30
Share repurchase amount first1.0 billion30
SG&A expenses4.0 billion30
R&D expenses892 million30
Net cash from operating activities3.8 billion30
Net cash from operating activities3.5 billion30
Long-term debt rating S&P Global RatingsA+30
Long-term debt rating Moody's Investors ServiceAa330
Gross profit margin52.530
Dividend per share Q1 and0.6330
Dividend per share Q1 and0.5930
Common shares repurchased11.6 million30
Cash taxes paid856 million30
Cash and cash equivalents at June 305.1 billion30
Cash and cash equivalents at December 318.5 billion30
CGM systems sales4.1 billion30
CGM systems sales3.6 billion30
CGM organic growth8.630
Available for repurchase under program5.6 billion30
Abbott Laboratories, published 2026-07-16, period 2026-Q2
Reported sales growth total company Q213.029
Reported sales growth total company H110.529
Comparable sales growth total company Q24.829
comparable sales growth total company 1H4.329
Abbott Laboratories, published 2026-04-29, period 2026-Q1
Working capital prior year end9.5 billion28
Working capital7.1 billion28
SG&A expenses prior year3.021 billion28
SG&A expenses3.7 billion28
Repurchase authorization remaining6.7 billion28
R&D expenses prior year71628
R&D expenses76728
Quarterly dividend per share prior year0.5928
Quarterly dividend per share0.6328
Net cash from operating activities prior year1.402 billion28
Net cash from operating activities1.3 billion28
Gross profit margin percentage prior year52.8 percent28
Gross profit margin percentage52.4 percent28
Cash taxes paid prior year25528
Cash taxes paid26628
Cash and cash equivalents prior year end8.5 billion28
Cash and cash equivalents6.8 billion28
CGM systems sales prior year1.7 billion28
CGM systems sales2.0 billion28
Abbott Laboratories, published 2026-02-20, period FY2025
yen-denominated term loan hedge value$589 million26
yen-denominated term loan hedge value$583 million26
working capital December 31$9.5 billion26
working capital December 31$9.5 billion26
women managers percentage44%26
total foreign currency forward contracts$20,495 million26
total foreign currency forward contracts$23,191 million26
total debt outstanding$12.9 billion26
remaining authorization 2024 repurchase program$6.7 billion26
rebates percentage of gross sales21.1%26
rebates percentage of gross sales18.6%26
rebates percentage of gross sales17.4%26
operating lease obligations due within$316 million26
operating lease obligations$1.4 billion26
nutritional products pediatric sales change 2025 excl fx-0.7%26
nutritional products operating earnings growth3.5%26
nutritional products adult sales growth 2025 excl fx2.7%26
nutritional products adult sales growth 2024 excl fx8.0%26
non-publicly traded equity securities$124 million26
non-publicly traded equity securities$91 million26
non-cash valuation allowance adjustments$7.5 billion26
net tax benefit from resolution of tax positions$70 million26
net tax benefit from resolution of tax positions$25 million26
net tax benefit from resolution of tax positions$80 million26
mutual funds fair value$323 million26
mutual funds fair value$313 million26
medical devices segment sales growth 2025 excl FX11.9%26
medical devices segment sales growth 2024 excl FX13.7%26
medical devices operating earnings growth17.2%26
medical devices operating earnings growth16.0%26
long-term debt fair value$12.8 billion26
long-term debt fair value$13.7 billion26
international sales percentage61%26
interest rate hedge contracts notional value$1.2 billion26
interest rate hedge contracts notional value$2.2 billion26
interest payments 2031 and thereafter$4.3 billion26
interest payments$377 million26
interest payments$386 million26
interest payments$395 million26
interest payments$401 million26
interest payments$485 million26
foreign currency forward contracts other notional value$13.1 billion26
FX forward contracts other notional value$16.2 billion26
FX forward contracts cash flow hedges notional value$7.4 billion26
FX forward contracts cash flow hedges notional value$7.0 billion26
FX forward contracts all other currencies$8,156 million26
FX forward contracts all other currencies$8,832 million26
FX forward contracts Japanese Yen$1,313 million26
FX forward contracts Japanese Yen$1,479 million26
FX forward contracts Euro$9,137 million26
FX forward contracts Euro$10,954 million26
FX forward contracts Chinese Yuan$1,889 million26
FX forward contracts Chinese Yuan$1,926 million26
Fixed asset impairment charges$28 million26
Fixed asset impairment charges$12 million26
Excess tax benefits from share-based compensation$92 million26
Excess tax benefits from share-based compensation$50 million26
Excess tax benefits from share-based compensation$22 million26
Established pharma sales growth 2025 excl FX7.4%26
Established pharma sales growth 2024 excl FX9.2%26
Established pharma operating earnings growth4.7%26
Equity securities fair value$20 million26
equity securities fair value$10 million26
emerging markets sales percentage37%26
emerging markets growth5.1%26
emerging markets growth8.2%26
dividends per share increase7.1 percent26
dividends per share$2.4026
dividends per share$2.2426
dividends paid$4.1 billion26
dividends paid$3.8 billion26
diagnostics segment sales decrease 2025 excl fx-4.5%26
diagnostics segment sales decrease 2024 excl fx-3.9%26
diagnostics operating earnings decrease-16.1%26
deduction tax benefit available$440 million26
debt maturing in 2031 and thereafter$7.4 billion26
debt maturing in$650 million26
debt maturing in$591 million26
debt maturing in$653 million26
debt maturing in$700 million26
debt maturing in$3.0 billion26
debt assumed prior acquisition repaid$197 million26
current and long-term investment securities fair value$1.3 billion26
current and long-term investment securities fair value$1.2 billion26
consolidated gross revenues subject to rebates44%26
common shares repurchased 2025 cost$604 million26
common shares repurchased4.8 million26
common shares repurchased 2024 cost$1.1 billion26
common shares repurchased10.2 million26
common shares repurchased 2023 cost$1.0 billion26
common shares repurchased9.8 million26
cash and cash equivalents December 31$8.5 billion26
cash and cash equivalents December 31$7.6 billion26
bridge term loan facility commitment$20.0 billion26
Yen-denominated term loan principal¥92.0 billion26
Yen-denominated term loan original principal¥59.8 billion26
Yen-denominated term loan net proceeds$201 million26
TCJA transition tax obligation remaining balance$205 million26
selling, general and administrative expenses prior year$11.7 billion26
selling, general and administrative expenses$10.9 billion26
selling, general and administrative expenses$12.3 billion26
Russia and Ukraine operations percentage of total revenues2 percent26
Restructuring remaining liabilities$180 million26
Restructuring payments$94 million26
Research and development expenses prior year$2.8 billion26
Research and development expenses$2.7 billion26
Research and development expenses$2.9 billion26
Other (income) expense, net$548 million26
Other (income) expense, net$376 million26
Other (income) expense, net$479 million26
Net cash from operating activities$9.6 billion26
Net cash from operating activities$8.6 billion26
Net cash from operating activities$7.3 billion26
Malaysian tax assessment$413 million26
Interest expense, net$185 million26
Interest expense, net$215 million26
IRS SNOD$443 million26
IRS SNOD$417 million26
IRS SNOD 2017 and$192 million26
Exact Sciences purchase price per share$10526
Exact Sciences net debt$1.8 billion26
Exact Sciences acquisition equity value$21 billion26
Exact Sciences acquisition enterprise value$23 billion26
Euro-denominated 0.875% Notes repaid USD equivalent$1.2 billion26
Euro-denominated 0.875% Notes repaid€1.14 billion26
Euro-denominated 0.10% Notes repaid USD equivalent$640 million26
Euro-denominated 0.10% Notes repaid€590 million26
Capital expenditures$2.2 billion26
Capital expenditures$2.2 billion26
Capital expenditures$2.2 billion26
CSI other net assets$116 million26
CSI in-process research and development asset$15 million26
CSI acquisition purchase price$851 million26
COVID-19 testing-related sales Rapid Diagnostics prior year$725 million26
COVID-19 testing-related sales Rapid Diagnostics$285 million26
CGM sales prior year$6.4 billion26
CGM sales$7.6 billion26
3.875% Notes repaid$500 million26
3.40% Notes repaid$1.05 billion26
2024 share repurchase authorization$7 billion26
2021 share repurchase authorization$5 billion26
2.95% Notes repaid$1.0 billion26
Abbott Laboratories, published 2026-01-22, period 2025-Q4
Continuous glucose monitors sales (4Q25)$2.0 billion25
Continuous glucose monitors reported growth (4Q25)15.025
Continuous glucose monitors organic growth (4Q25)12.225
Abbott Laboratories, published 2025-10-29, period 2025-Q3
Working capital at Sep 3010.3 billion24
Working capital at Dec 319.5 billion24
Gross profit margin51.7%24
Gross profit margin51.4%24
Gross profit margin 9M52.4%24
Gross profit margin 9M51.0%24
Dividend per share Q1-Q30.5924
Dividend per share Q1-Q30.5524
Cash and cash equivalents at Sep 307.5 billion24
Cash and cash equivalents at Dec 317.6 billion24
COVID-19 testing-related sales69 million24
COVID-19 testing-related sales265 million24
COVID-19 testing-related sales 9M208 million24
COVID-19 testing-related sales 9M571 million24
CGM systems sales prior year4.7 billion24
CGM systems sales5.6 billion24
Abbott Laboratories, published 2025-10-15, period 2025-Q3
Continuous glucose monitor sales$2.0 billion23
Continuous glucose monitor growth20.5% reported, 17.2% organic23
Abbott Laboratories, published 2025-07-30, period 2025-Q2
Cash taxes paid945 million22
Cash taxes paid747 million22
Abbott Laboratories, published 2025-07-17, period 2025-Q2
Continuous glucose monitors sales$1.9 billion21
Abbott Laboratories, published 2025-04-30, period 2025-Q1
Working capital prior period9.5 billion20
Working capital10.1 billion20
Share repurchase program Dec 2021 unused portion293 million20
Share repurchase authorization Oct7 billion20
SG&A expense increase %3.5%20
SG&A expense increase102 million20
Restructuring payments4 million20
Restructuring asset impairment charges12 million20
Remaining restructuring liability30 million20
Remaining Performance Obligations Medical Devices423 million20
Remaining Performance Obligations Diagnostic5.7 billion20
R&D expenses % of net sales4.6%20
R&D expenses716 million20
R&D expense increase32 million20
Quarterly dividend per share prior year0.5520
Quarterly dividend per share0.5920
Post-employment medical and dental plan contributions prior year28 million20
Post-employment medical and dental plan contributions75 million20
Other income, net prior year111 million20
Other income, net127 million20
Net cash from operating activities increase392 million20
Net cash from operating activities1.4 billion20
Interest expense, net prior year61 million20
Interest expense, net49 million20
IRS SNOD 2020 Federal tax year443 million20
IRS SNOD 2019 Federal tax year417 million20
IRS SNOD 2017 and 2018 Federal tax years192 million20
Gross profit margin percentage prior year50.5%20
Gross profit margin percentage52.8%20
Excess tax benefits associated with share-based compensation prior year25 million20
Excess tax benefits associated with share-based compensation73 million20
Dividend increase percentage7.3%20
Debt repayment March1.0 billion20
Cash taxes paid prior year225 million20
Cash taxes paid255 million20
Cash and cash equivalents prior period7.6 billion20
Cash and cash equivalents6.5 billion20
COVID-19 testing-related sales prior year204 million20
COVID-19 testing-related sales84 million20
CGM systems sales prior year1.5 billion20
CGM systems sales1.7 billion20
2020 SNOD estimated cash tax benefit440 million20
Abbott Laboratories, published 2025-04-16, period 2025-Q1
Diabetes Care CGM sales growth (reported)18.3 percent19
Diabetes Care CGM sales growth (organic)21.6 percent19
Diabetes Care CGM sales$1.7 billion19
Abbott Laboratories, published 2025-02-21, period FY2024
Women managers43%18
Rebates to gross sales18.6%18
Rebates to gross sales17.4%18
Rebates to gross sales17.6%18
Operating margin16.3%18
operating margin16.2%18
operating margin19.2%18
nutritional products segment operating margin17.9%18
nutritional products segment operating margin16.4%18
nutritional products segment operating margin9.5%18
medical devices segment operating margin32.4%18
medical devices segment operating margin31.4%18
medical devices segment operating margin30.0%18
international sales percentage61%18
established pharma segment operating margin23.7%18
established pharma segment operating margin21.4%18
emerging markets sales percentageapproximately 37%18
diagnostics segment operating margin22.2%18
diagnostics segment operating margin40.3%18
Yen-denominated term loan hedge583 million18
interest rate hedge contracts notional value2.2 billion18
foreign currency forward exchange contracts notional value (other)16.2 billion18
foreign currency forward exchange contracts notional value (cash flow hedges)7.0 billion18
fair value of mutual funds in rabbi trust313 million18
fair value of equity securities10 million18
carrying value of non-publicly traded equity securities91 million18
CGM sales6.4 billion18
Abbott Laboratories, published 2025-01-22, period 2024-Q4
Continuous glucose monitor sales$1.8 billion17
COVID-19 testing sales$176 million17
COVID-19 testing sales 12M$747 million17
Abbott Laboratories, published 2024-10-31, period 2024-Q3
Yen-denominated loan - Original amount¥59.8 billion16
Yen-denominated loan - Net proceeds$201 million16
Yen-denominated loan - Modified amount¥92.0 billion16
Working capital$8.9 billion16
Working capital$8.8 billion16
SG&A6.3% increase16
SG&A6.9% increase16
Restructuring asset impairment charges$22 million16
R&D expenses$713 million16
R&D expenses$672 million16
R&D expenses$2.1 billion16
R&D expenses$2.046 billion16
Remaining available for repurchase under 2021 program$659 million16
Rapid Diagnostics COVID-19 testing-related sales$553 million16
Rapid Diagnostics COVID-19 testing-related sales$1.2 billion16
Quarterly dividend per share$0.5516
Quarterly dividend per share$0.5116
Other income$121 million16
Other income$83 million16
Other income$222 million16
Other income$370 million16
New share repurchase authorization$7 billion16
Net cash from operating activities$5.7 billion16
Net cash from operating activities$4.2 billion16
Molecular Diagnostics COVID-19 testing-related sales$10 million16
Molecular Diagnostics COVID-19 testing-related sales$36 million16
Long-term debt rating - S&P Global RatingsAA-16
Long-term debt rating - Moody's Investors ServiceAa316
Interest expense, net$51 million16
Interest expense, net$69 million16
Interest expense, net$170 million16
Interest expense, net$182 million16
Gross profit margin percentage51.4%16
Gross profit margin percentage49.7%16
Gross profit margin percentage51.0%16
Gross profit margin percentage50.1%16
Euro notes repaid€1.14 billion16
Debt assumed as part of recent acquisition$197 million16
Core Laboratory Diagnostics COVID-19 testing-related sales$8 million16
Core Laboratory Diagnostics COVID-19 testing-related sales$16 million16
Common shares repurchasedapproximately 7 million16
Cash and cash equivalents$7.6 billion16
Cash and cash equivalents$6.9 billion16
CSI other net assets$116 million16
CSI in-process research and development asset$15 million16
CSI acquisition purchase price$851 million16
COVID-19 testing-related sales$265 million16
COVID-19 testing-related sales$305 million16
COVID-19 testing-related sales$571 million16
COVID-19 testing-related sales$1.3 billion16
CGM systems sales$4.7 billion16
CGM systems sales$3.9 billion16
Available revolving credit$5 billion16
Approximate amount of Euro notes repaid in USD$1.2 billion16
Amount spent on share repurchases$750 million16
Abbott Laboratories, published 2024-10-16, period 2024-Q3
Share repurchase program authorized7 billion15
Reported sales growth4.915
Quarterly dividend per share$0.5515
Organic sales growth (base business, excluding COVID-19)8.215
Continuous glucose monitor sales1.6 billion15
Consecutive years of dividend increases5215
COVID-19 testing sales (3Q24)265 million15
COVID-19 testing sales (3Q23)305 million15
Abbott Laboratories, published 2024-07-31, period 2024-Q2
Working capital$9.4 billion14
SG&A expenses increase$393 million14
SG&A expenses increase$196 million14
Restructuring charges$59 million14
R&D expenses increase$13 million14
R&D expenses decrease$17 million14
Other (Income) Expense, net$101 million14
Other (Income) Expense, net$10 million14
Net cash from operating activities$3.0 billion14
Interest expense, net$119 million14
Interest expense, net$58 million14
Gross profit margin percentage (6 months)50.8%14
Gross profit margin percentage51.1%14
FreeStyle Libre sales$3.0 billion14
Dividend per share$0.5514
Cash taxes paid$747 million14
Cash and cash equivalents$7.0 billion14
CSI acquisition purchase price$851 million14
COVID-19 testing-related sales$102 million14
Asset impairment charges$28 million14
Abbott Laboratories, published 2024-07-18, period 2024-Q2
FreeStyle Libre sales (2Q24)$1.6 billion13
FreeStyle Libre organic growth (2Q24)20.4%13
Abbott Laboratories, published 2024-04-17, period 2024-Q1
Quarterly dividend$0.55 per share11
FreeStyle Libre sales$1.5 billion11
Abbott Laboratories, published 2024-02-16, period FY2023
Yen denominated term loan$419 million10
Yen denominated term loan$446 million10
Working capital$8.8 billion10
working capital$9.7 billion10
women managers pct42%10
wic states4010
unsecured credit facility$5 billion10
total debt outstanding$14.7 billion10
tcja transition tax obligation remaining$598 million10
tax positions net expense$80 million10
tax positions net benefit$20 million10
tax positions net benefit$55 million10
share repurchases9.8 million shares10
share repurchases32.3 million shares10
share repurchases16.6 million shares10
share repurchase cost$1.025 billion10
share repurchase cost$3.65 billion10
share repurchase cost$2.016 billion10
share repurchase authorization remaining$1.41 billion10
restructuring fixed asset impairment$31 million10
restructuring fixed asset impairment$4 million10
restructuring charges$144 million10
restructuring charges$234 million10
restructuring charges 2021 streamline$68 million10
restructuring charges 2021 diagnostic$441 million10
rebates and allowances pct17.4%10
rebates amount3.9 billion10
rd expenses$2.7 billion10
rd expenses$2.9 billion10
rd expenses$2.7 billion10
quarterly dividend increase pct7.8%10
prior quarterly dividend0.5110
pending infant formula lawsuits99310
other income$479 million10
other income$321 million10
other income$277 million10
operating margin pct16.2%10
operating margin pct19.2%10
operating margin pct19.6%10
operating lease obligations$1.362 billion10
operating lease due within$278 million10
nutritional operating margin16.4%10
nutritional operating margin9.5%10
nutritional operating margin21.3%10
non publicly traded equity$88 million10
non publicly traded equity$83 million10
new quarterly dividend0.5510
medical devices operating margin31.4%10
medical devices operating margin30.0%10
medical devices operating margin31.3%10
long term debt rating S&PAA-10
long term debt rating MoodysAa310
long term debt fair value$14.8 billion10
long term debt fair value$16.3 billion10
long term debt average interest rate3.6%10
long term debt average interest rate3.5%10
long term debt14.7 billion10
litigation loss contingency range$30 million to $45 million10
litigation accrual$40 million10
IRS SNOD 2019 federal tax year$417 million10
investment securities fair value$1.2 billion10
investment securities fair value$1.1 billion10
international sales pct61%10
interest rate hedge contracts notional$2.2 billion10
interest rate hedge contracts notional$2.9 billion10
interest payments 2029 and thereafter$5.0 billion10
interest payments$385 million10
interest payments$391 million10
interest payments$474 million10
interest payments$508 million10
interest payments$526 million10
interest expense net$252 million10
interest expense net$375 million10
gross profit margin50.3%10
gross profit margin51.5%10
gross profit margin52.2%10
foreign currency forward total notional$21,160 million10
foreign currency forward total notional$19,746 million10
foreign currency forward total fair value$(62) million10
foreign currency forward total fair value$186 million10
foreign currency forward other notional$8,189 million10
foreign currency forward other notional$8,029 million10
foreign currency forward other fair value$(54) million10
foreign currency forward other fair value$89 million10
foreign currency forward JPY notional$1,635 million10
foreign currency forward JPY notional$1,797 million10
foreign currency forward JPY fair value$24 million10
foreign currency forward JPY fair value$(7) million10
foreign currency forward EUR notional$9,221 million10
foreign currency forward EUR notional$7,656 million10
foreign currency forward EUR fair value$(35) million10
foreign currency forward EUR fair value$92 million10
foreign currency forward contracts intercompany$13.8 billion10
foreign currency forward contracts intercompany$12.0 billion10
foreign currency forward contracts cash flow hedge$7.3 billion10
foreign currency forward contracts cash flow hedge$7.7 billion10
foreign currency forward CNY notional$2,115 million10
foreign currency forward CNY notional$2,264 million10
foreign currency forward CNY fair value$3 million10
foreign currency forward CNY fair value$12 million10
excess tax benefits$22 million10
excess tax benefits$43 million10
excess tax benefits$145 million10
established pharma operating margin23.8%10
established pharma operating margin18.8%10
equity securities fair value$12 million10
equity securities fair value$9 million10
equity securities 20pct decrease impact$2 million10
equity investment impairments$39 million10
equity investment impairments$45 million10
emerging markets sales pct38%10
dividends paid3.556 billion10
dividends paid3.309 billion10
dividend per share2.0810
dividend per share1.9210
dividend increase pct8.3%10
diagnostics operating margin24.4%10
diagnostics operating margin40.2%10
deferred compensation mutual funds$314 million10
deferred compensation mutual funds$298 million10
debt repaid september 2023 usd$1.2 billion10
debt repaid september 2023 eur€1.14 billion10
debt repaid november$1.05 billion10
debt principal payments 2029 and thereafter$8.0 billion10
debt principal payments$651 million10
debt principal payments$656 million10
debt principal payments$3.0 billion10
debt principal payments$1.5 billion10
debt principal payments$1.1 billion10
debt maturing$1.1 billion10
debt assumed acquisition repaid$197 million10
CSI net assets$114 million10
CSI IPR&D$15 million10
CSI deferred tax assets$46 million10
CSI acquisition purchase price$851 million10
COVID-19 testing sales730 million10
COVID-19 testing sales1.6 billion10
contingent consideration fair value reduction$42 million10
consolidated indebtedness14.7 billion10
cash and short-term investments7.3 billion10
cash and equivalents$6.9 billion10
cash and equivalents$9.9 billion10
Capex$2.2 billion10
Capex$1.8 billion10
Capex$1.9 billion10
actuarial losses medical/dental plans40 million10
actuarial losses defined benefit plans1.8 billion10
Abbott Laboratories, published 2024-01-24, period 2023-Q4
Quarterly dividend per share$0.559
FreeStyle Libre sales$1.4 billion9
Abbott Laboratories, published 2023-11-01, period 2023-Q3
working capital Sept 309.6 billion8
working capital Dec 319.7 billion8
unrecognized tax benefits possible decreaseapproximately 55 million8
share repurchases 9Mapproximately 7 million shares8
share repurchase program remaining1.709 billion8
share repurchase cost 9M725 million8
quarterly dividend0.51 per share8
quarterly dividend0.47 per share8
net cash from operating activities 9Mapproximately 4.2 billion8
net cash from operating activities 9M7.2 billion8
lines of credit available5.0 billion8
gross profit margin49.7 percent8
gross profit margin50.7 percent8
gross profit margin 9M50.1 percent8
gross profit margin 9M52.1 percent8
dividend increase percent8.5 percent8
debt repaid euro notes USDapproximately 1.2 billion8
debt repaid euro notes€1.14 billion8
debt repaid acquisition assumptionapproximately 197 million8
cash taxes paid 9Mapproximately 1.180 billion8
cash taxes paid 9Mapproximately 987 million8
cash and cash equivalents Sept 306.7 billion8
cash and cash equivalents Dec 319.9 billion8
SG&A expensesdecreased $8 million, or 0.3 percent8
SG&A expenses 9Mdecreased $50 million, or 0.6 percent8
Rapid Diagnostics COVID 19 sales 9M1.2 billion8
Rapid Diagnostics COVID 19 sales 9M6.9 billion8
R&D expensesdecreased $110 million, or 14.0 percent8
R&D expenses 9Mdecreased $122 million, or 5.6 percent8
Other income net83 million8
Other income net93 million8
Other income net 9M370 million8
Other income net 9M253 million8
Molecular Diagnostics COVID 19 sales 9M36 million8
Molecular Diagnostics COVID 19 sales 9M375 million8
Interest expense net69 million8
Interest expense net86 million8
Interest expense net 9M182 million8
Interest expense net 9M309 million8
IRS SNOD amount417 million8
FreeStyle Libre sales 9M3.9 billion8
FreeStyle Libre sales 9M3.1 billion8
FreeStyle Libre growth percent26.2 percent8
Core Laboratory COVID-19 sales 9M16 million8
Core Laboratory COVID-19 sales 9M51 million8
CSI other net assetsapproximately 116 million8
CSI net deferred tax assetsapproximately 31 million8
CSI acquisition total851 million8
CSI acquisition price20 per common share8
CSI IPR&D15 million8
COVID-19 testing salesapproximately 305 million8
COVID-19 testing salesapproximately 1.7 billion8
COVID-19 testing sales 9Mapproximately 1.3 billion8
COVID-19 testing sales 9Mapproximately 7.3 billion8
Abbott Laboratories, published 2023-10-18, period 2023-Q3
Quarterly dividend per share$0.517
FreeStyle Libre sales$1.4 billion7
COVID-19 testing sales 9M23$1.298 billion7
COVID-19 testing sales 9M22$7.299 billion7
COVID-19 testing sales 3Q23$305 million7
COVID-19 testing sales 3Q22$1.671 billion7
Abbott Laboratories, published 2023-08-03, period 2023-Q2
Working Capital9.2 billion6
Working Capital9.7 billion6
Share Repurchases725 million6
Rapid Diagnostics COVID-19 Testing Sales954 million6
Rapid Diagnostics COVID-19 Testing Sales5.3 billion6
Quarterly Dividend per Share0.516
Quarterly Dividend per Share0.476
Net Cash from Operating Activities2.3 billion6
Molecular Diagnostics COVID-19 Testing Sales28 million6
Molecular Diagnostics COVID-19 Testing Sales321 million6
Gross Profit Margin51.7%6
Gross Profit Margin - Second Quarter50.1%6
Gross Profit Margin52.8%6
Gross Profit Margin - First50.3%6
FreeStyle Libre Sales2.5 billion6
FreeStyle Libre Sales2.1 billion6
Core Laboratory Diagnostics COVID-19 Testing Sales11 million6
Core Laboratory Diagnostics COVID-19 Testing Sales40 million6
Common Shares Repurchased7 million6
Cash and Cash Equivalents7.8 billion6
Cash and Cash Equivalents9.9 billion6
Cash Taxes Paid837 million6
Cash Taxes Paid657 million6
COVID-19 Testing Sales263 million6
COVID-19 Testing Sales2.3 billion6
COVID-19 Testing Sales993 million6
COVID-19 Testing Sales5.6 billion6
Available Share Repurchase Authorization1.709 billion6
Abbott Laboratories, published 2023-07-20, period 2023-Q2
FreeStyle Libre sales$1.3 billion5
Abbott Laboratories, published 2023-05-04, period 2023-Q1
Cash and cash equivalents9,1614
Abbott Laboratories, published 2023-04-19, period 2023-Q1
FreeStyle Libre sales$1.2 billion3
FreeStyle Libre U.S. growthapproximately 50 percent3

Abbott Laboratories Development

How Abbott Laboratories has developed since 2023: one paragraph per period on revenue, earnings, cash flow and drivers, most recent period first, grouped by year. NadirAlpha methodology

FY2026: Abbott Laboratories

Abbott generated revenue of USD 11,164 million in Q1, USD 12,593 million in Q2, and USD 13,013 million in Q3 2026, with reported sales growth of 7.8 percent, 13.0 percent, and 14.5 percent respectively 28 29 31. The completion of the Exact Sciences acquisition on March 23, 2026 for approximately $20.6 billion, funded primarily through $20.0 billion in long-term debt issuance, added oncology diagnostics products including Cologuard, Oncotype DX, and Cancerguard to Abbott's Diagnostic Products portfolio 28. Medical Devices showed consistent organic growth led by double-digit expansion in Electrophysiology, Rhythm Management, and Heart Failure, while Continuous Glucose Monitoring systems reached $4.1 billion in the first half of 2026 30. Abbott raised full-year adjusted diluted EPS guidance in Q2 and reaffirmed full-year comparable sales growth of approximately 6.0 percent and adjusted diluted EPS of $5.50 to $5.55 in Q3 31.

FY2025: Abbott Laboratories

Abbott reported net sales of 44,328 million for fiscal year 2025, up 5.7 percent on a reported basis and 5.5 percent on an organic basis 25. The Medical Devices segment recorded sales growth of 11.9 percent excluding foreign exchange, with double-digit gains in Diabetes Care, Heart Failure, Electrophysiology, Structural Heart, and Rhythm Management 26. Diagnostics segment sales declined 4.5 percent excluding foreign exchange, driven by lower demand for COVID-19 tests and challenging market conditions in China 26. The operating margin increased to 18.2 percent from 16.3 percent in 2024 reflecting margin improvement initiatives, and net cash from operating activities totaled 9,566 million 26. Following the fiscal year end, Abbott announced a definitive agreement to acquire Exact Sciences Corporation for an enterprise value of approximately $23 billion, with the transaction expected to close in Q2 2026 25.

FY2024: Abbott Laboratories

Abbott's full-year 2024 net sales reached USD 41,950 million, a reported increase of 4.6% 17, with Medical Devices the primary growth driver, expanding 12.4% and led by Diabetes Care where CGM systems generated $6.4 billion in sales 18. The Diagnostic Products segment declined 3.9% in 2024 as lower demand for COVID-19 tests continued to weigh on reported revenue comparisons throughout the year 18. Full-year GAAP diluted EPS was 7.64 17, while adjusted diluted EPS of $4.67 reached the upper end of the initial guidance range 17. Gross profit margins improved to 50.9% of net sales from 50.3% in 2023, reflecting favorable impacts of margin improvement initiatives partially offset by foreign exchange 18. Operating cash flow totaled USD 8,558 million, higher than the prior year due to stronger segment earnings and improved working capital management 18.

FY2023: Abbott Laboratories

Abbott's full-year 2023 reported sales of USD 40,109 million decreased 8.1 percent, driven by the anticipated normalization of COVID-19 testing-related sales from $8.4 billion in 2022 to $1.6 billion in 2023 10. Excluding COVID-19 testing impact and foreign exchange, the company's total net sales increased 11.7 percent, with Medical Devices segment sales growing 15.1 percent and FreeStyle Libre continuous glucose monitoring system sales reaching $5.3 billion, a 25.5 percent increase over 2022 10. Full-year GAAP diluted EPS was 3.26 and adjusted diluted EPS was $4.44 9. Abbott Laboratories completed the acquisitions of Cardiovascular Systems Inc. for $851 million and Bigfoot Biomedical during the year, expanding its vascular and diabetes management portfolios, while receiving multiple FDA approvals including for the AVEIR dual-chamber leadless pacemaker system, described as the world's first dual-chamber leadless pacing system 10. Net cash from operating activities was USD 7,261 million, compared to $9.6 billion in 2022, reflecting lower operating earnings and increased working capital payments 10.

Glossary

  • Revenue: Revenue from contracts with customers, net of sales deductions, as the company itself reports it; not total output, gross revenue, GMV or order intake.
  • Op. income: The operating line of the income statement; EBIT only as a marked fallback, never pre-tax or ordinary income.
  • Net income: Net income attributable to the shareholders of the parent, after discontinued operations; not the result including minority interests, not comprehensive income.
  • EPS: Diluted earnings per share attributable to the shareholders of the parent; a printed figure always beats a calculated one, calculated values are marked.
  • EPS adj.: Adjusted earnings per share, verbatim and company-defined (non-GAAP).
  • FCF: Free cash flow = operating cash flow minus capital expenditure on property, plant and equipment; the company's own free cash flow figure is shown separately.
  • OCF: Cash flow from operating activities as reported; IFRS companies may show interest paid in financing cash flow, so the figure is not always comparable.
  • Cash: Cash and cash equivalents, without securities unless the company reports them as part of the position.
  • Net Debt: Net debt = financial debt excluding lease liabilities minus cash at the same reporting date; the company's own net position may differ.
  • *: derived, the formula is in the hover
  • ≈: calculated, approximation
  • ~: uncertain; the value stays visible, verdicts do not use it
  • °: repaired by a targeted query against the document, or curated with documentary evidence
  • EBIT: EBIT as a fallback: the income statement carries no operating line
  • basic: basic earnings per share as a fallback when diluted is missing

Sources: quarterly reports, annual reports and investor relations documents

All original documents NadirAlpha used for this report on Abbott Laboratories stock: quarterly and annual reports, earnings releases and investor relations documents, sorted by publication, the document type is the link. NadirAlpha methodology

48 documents · 2016 to 2026 · SEC EDGAR (USA)
Sources for Abbott Laboratories stock: 48 original documents, 2016 to 2026. Compiled by NadirAlpha.
#Document typePublished
#1 / #1018-K-EX99.1 earnings release2023-01-25
#210-K annual report2023-02-17
#38-K-EX99.1 earnings release2023-04-19
#4 / #10410-Q quarterly report2023-05-04
#58-K-EX99.1 earnings release2023-07-20
#610-Q quarterly report2023-08-03
#78-K-EX99.1 earnings release2023-10-18
#810-Q quarterly report2023-11-01
#9 / #1098-K-EX99.1 earnings release2024-01-24
#1010-K annual report2024-02-16
#118-K-EX99.1 earnings release2024-04-17
#1210-Q quarterly report2024-05-02
#138-K-EX99.1 earnings release2024-07-18
#1410-Q quarterly report2024-07-31
#158-K-EX99.1 earnings release2024-10-16
#1610-Q quarterly report2024-10-31
#17 / #1178-K-EX99.1 earnings release2025-01-22
#1810-K annual report2025-02-21
#198-K-EX99.1 earnings release2025-04-16
#20 / #12010-Q quarterly report2025-04-30
#218-K-EX99.1 earnings release2025-07-17
#2210-Q quarterly report2025-07-30
#238-K-EX99.1 earnings release2025-10-15
#2410-Q quarterly report2025-10-29
#25 / #1258-K-EX99.1 earnings release2026-01-22
#2610-K annual report2026-02-20
#278-K-EX99.1 earnings release2026-04-16
#2810-Q quarterly report2026-04-29
#29 / #1298-K-EX99.1 earnings release2026-07-16
#3010-Q quarterly report2026-07-28
#31 / #1318-K-EX99.1 earnings release2026-10-21
Older sources (+17)
Older sources for Abbott Laboratories, 17 documents
#Document typePublished
#20110-K annual report2016-05-04
#20310-Q quarterly report2016-08-03
#20210-K annual report2017-02-17
#20410-Q quarterly report2017-08-02
#20510-K annual report2018-02-16
#21510-Q quarterly report2018-08-01
#20910-K annual report2019-02-22
#20610-Q quarterly report2019-05-01
#20710-Q quarterly report2019-07-31
#20810-Q quarterly report2019-10-31
#21310-K annual report2020-02-21
#21010-Q quarterly report2020-04-29
#21110-Q quarterly report2020-07-29
#21210-Q quarterly report2020-11-04
#21410-Q quarterly report2021-05-05
#21610-Q quarterly report2021-08-04
#21710-Q quarterly report2021-11-03

Abbott Laboratories Stock FAQ

Is there a management forecast (guidance) for FY2026?

Yes. Management has issued targets for FY2026, including EPS (non-GAAP). The guidance tracking chapter shows all targets and checks them against the actuals reported later; neutral, with no estimate of our own.

Does Abbott Laboratories pay a dividend?

The filings report on the dividend; most recent entry: dividend per share 0.63 (2026-Q2) (as reported, no assessment of our own). Details with source links are in the report chapters.

Where can I find the official investor relations documents of Abbott Laboratories?

NadirAlpha links all 48 original filings used (SEC filings) in the sources chapter: quarterly report, earnings release, annual report, each with type, publication date and a direct link; every figure in the report carries a source number.

More reports by NadirAlpha

Recently updated

C3.ai (AI)US12468P1049Figures as of Updated Revenue decelerating · Free cash flow turned positiveBaxter International (BAX)US0718131099Figures as of Updated Net income turned positive · Guidance raisedEstée Lauder Companies (EL)US5184391044Figures as of Updated Operating income turned positive · Guidance initiated

Comparable stocks by NadirAlpha

FactSet Research Systems (FDS)US3030751057Figures as of Updated Strategic pivot · New marketFair Isaac (FICO)US3032501047Figures as of Updated Revenue decelerating · Guidance raisedServiceNow (NOW)US81762P1021Figures as of Updated Net cash to net debt · Operating income halvedProcore Technologies (PCOR)US74275K1088Figures as of Updated Acquisition · Operating income turned positiveSkyworks Solutions (SWKS)US83088M1027Figures as of Updated Revenue decelerating · AcquisitionAdtran (ADTN)US00486H1059Figures as of Updated Margin compressing · Guidance cut

All reports · US Stocks (52)